Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 11Gastrointestinal 6Breast 5Thoracic 3Tumor-Agnostic 2Other neoplasm 2Lymphoid 2Head & Neck 2Other hematologic neoplasm 1Other 1Myeloid 1Gynecologic 1Dermatologic 1Classical hematology 1CNS 1

Conditions

Non-melanoma Skin Cancer 1

Interventions

pembrolizumab 326Nivolumab 289Ipilimumab 260Cyclophosphamide 194aldesleukin 145Interleukin-2 109fludarabine phosphate 107Temozolomide 83fludarabine 81Dacarbazine 81Radiotherapy 74trametinib 73Vemurafenib 69dabrafenib 66Biopsy 65sargramostim 50Bevacizumab 50Radiosurgery 49Paclitaxel 49Peripheral Blood Stem Cell Transplantation 48Magnetic Resonance Spectroscopy 48Carboplatin 48Imiquimod 47Aminolevulinic Acid 47binimetinib 45Cisplatin 45CTLA-4 Antigen 43cemiplimab 42Specimen Handling 42atezolizumab 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Vitamin E × Dermatologic × Clear all
NCT00392561 2023-04-26

BEST

University of Chicago

Phase NA Completed
7,000 enrolled
Dermatologic

Non-melanoma Skin Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡